|
|
News Breaks | | | | February 6, 2013 | | 09:02 EDT |  | SGEN | Seattle Genetics initiates two Phase I trials of SGN-CD19A
Seattle Genetics announced the initiation of two phase I clinical trials of SGN-CD19A, one for patients with B-cell acute lymphoblastic leukemia and one for patients with B-cell non-Hodgkin lymphomas. SGN-CD19A utilizes Seattle Genetics’ industry-leading antibody-drug conjugate technology. The trials are designed to assess the safety and antitumor activity of SGN-CD19A, an ADC targeted to CD19. The studies are phase I, open-label, dose-escalation clinical trials. The primary endpoints are to estimate the maximum tolerated dose and to evaluate the safety of SGN-CD19A. In addition, the trials will evaluate antitumor activity, pharmacokinetics, progression-free survival and overall survival. One trial will enroll adult and pediatric patients with relapsed or refractory B-cell ALL, as well as patients with Burkitt lymphoma or leukemia or B-cell lymphoblastic lymphoma. The dose escalation portion of the study is designed to evaluate both weekly and every three week schedules and will enroll approximately 80 patients at multiple centers in the United States. A second trial will enroll patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and mantle cell lymphoma. The dose escalation portion of the trial will evaluate SGN-CD19A administered every three weeks and will enroll approximately 25 patients at multiple centers in the United States. | |
|
News For SGEN From The Last 14 Days Check below for free stories on SGEN the last two weeks. |
|
|
| May 14, 2013 | | 09:04 EDT | | SGEN | Seattle Genetics announces ADCETRIS supplemental filing accepted by FDA
 Subscribe for More Information | | | May 7, 2013 | | 16:22 EDT |  | SGEN | Seattle Genetics reports Q1 EPS (14c), consensus (20c)
Subscribe for More Information | |
|
|
|
|
|
|
